Genomma Lab InternacionalB de CVMEX:LABB +0.66%66 Earnings Yield (Joel Greenblatt) % is 13.61% as of Mar. 2026, which is 22% above its 10-year median of 11.14. GuruFocus rates MEX:LABB with a GF Score™ of 66/100 and a GF Value™ of MXN17.66 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,012 Drug Manufacturers companies, Genomma Lab InternacionalB de CV ranks better than 91.8% on this metric.
Genomma Lab InternacionalB de CV's Enterprise Value for the quarter that ended in Mar. 2026 was MXN23,005 Mil.
Genomma Lab InternacionalB de CV's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was MXN3,131 Mil. Genomma Lab InternacionalB de CV's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 13.61%.
The historical rank and industry rank for Genomma Lab InternacionalB de CV's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
MEX:LABB'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -14.4 Med: 11.14 Max: 16.54
Current: 16
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Genomma Lab InternacionalB de CV was 16.54%. The lowest was -14.40%. And the median was 11.14%.
MEX:LABB's Earnings Yield (Joel Greenblatt) % is ranked better than 91.8% of 1012
companies
in the Drug Manufacturers industry
Industry Median: 3.19
vs MEX:LABB: 16.00
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Genomma Lab InternacionalB de CV's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 19.68%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Genomma Lab InternacionalB de CV's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN3,131 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 13.61% mean?
Genomma Lab InternacionalB de CV (MEX:LABB) has a Earnings Yield (Joel Greenblatt) % of 13.61% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 22% above median its historical median of 11.14. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #83 out of 1012 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is Genomma Lab InternacionalB de CV's Earnings Yield (Joel Greenblatt) % too high?
Genomma Lab InternacionalB de CV's current Earnings Yield (Joel Greenblatt) % of 13.61% is 22% above median its 10-year median of 11.14. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.19. Genomma Lab InternacionalB de CV's value of 13.61% is 326.6% above this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #83 out of 1012 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #83 out of 1012 companies for Earnings Yield (Joel Greenblatt) %. This places Genomma Lab InternacionalB de CV in the top 8% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.19. Genomma Lab InternacionalB de CV's value of 13.61% is 326.6% above this benchmark. While the company's 10-year median is 11.14 vs. the industry median of 3.19, Genomma Lab InternacionalB de CV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.19, based on 1,012 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current Earnings Yield (Joel Greenblatt) % of 13.61% is 326.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current Earnings Yield (Joel Greenblatt) % is 13.61%, which is 22% above median its own 10-year median of 11.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.66, compared to a current price of MXN15.33 — trading 13.2% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 13.61%, which is 22% above median its 10-year median of 11.14 and 326.6% above the Drug Manufacturers industry median of 3.19. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current Earnings Yield (Joel Greenblatt) % is 13.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.33 is trading 13.2% below its estimated GF Value™ of MXN17.66.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
Earnings Yield (Joel Greenblatt) %: 13.61% (22% above median its 10-year median of 11.14)
GF Value™: MXN17.66 vs. price of MXN15.33 (13.2% below fair value)
Industry Position: 326.6% above the Drug Manufacturers median (#83 of 1012)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
